Profusa shares are trading higher after company announced it will acquire the PanOmics multi-omics diagnostics platform from BioInsights LLC for approximately $30 million in stock.

Benzinga Newsdesk www.benzinga.com Positive 94.3%

Neg 0% Neu 0% Pos 94.3%

Comments

No comments yet. Be the first!